Coya Therapeutics (NASDAQ:COYA) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Coya Therapeutics (NASDAQ:COYA) issued its earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08, Zacks reports. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%.

Coya Therapeutics Trading Up 0.6%

NASDAQ:COYA traded up $0.03 on Tuesday, reaching $4.67. 50,538 shares of the stock traded hands, compared to its average volume of 193,531. The company has a market capitalization of $109.56 million, a price-to-earnings ratio of -4.11 and a beta of 0.61. The company’s fifty day simple moving average is $4.86 and its 200 day simple moving average is $4.67. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of COYA. Trexquant Investment LP bought a new position in Coya Therapeutics in the 4th quarter worth approximately $145,000. Jump Financial LLC purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at approximately $198,000. OMERS ADMINISTRATION Corp bought a new position in shares of Coya Therapeutics during the fourth quarter valued at approximately $200,000. Jane Street Group LLC bought a new stake in Coya Therapeutics during the 4th quarter valued at $196,000. Finally, Dimensional Fund Advisors LP boosted its position in Coya Therapeutics by 58.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 31,429 shares of the company’s stock valued at $182,000 after purchasing an additional 11,648 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on COYA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Roth Capital initiated coverage on shares of Coya Therapeutics in a report on Friday, June 5th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Friday, June 12th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.33.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.